Premensstural Syndrom. Premenstrual tension syndrome
Conditions
Interventions
Intervention 1: In the control group who receive placebo: The participants take a dosage of 1200 mg per day taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Resear
Placebo
Prevention
Treatment - Drugs
In the control group who receive placebo: The participants take a dosage of 1200 mg per day taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Researcher calls the r
In the experimental group who attend health care educational program: The participants attend an educational program consisted of six two-hour educational sessions. The students complete the awareness
In the control group of the educational program: The participants only complete the awareness and insight questionnaire.
In the experimental group who receive Melissa officinalis capsules: The participants take a dosage of 1200 mg per day mg taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 c
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
76 Years to 72 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: willingness to participate in the study, obtaining informed consent from the parents of the students, not being in any stressful situation at the time of enrollment or during the study, presence in the educational sessions, not consuming vitamin supplements at the time of enrollment, not consuming hormonal medications such as contraceptives for at least 2 months before or during the study, a menstrual period of 3 to 7 days, lack of any underlying diseases such as thyroid diseases, diabetes mellitus and psychiatric disease. Exclusion criteria: the children’s willingness to leave the study, the request of the parents for exclusion of their children from the study, occurrence of a stressful event for the students or their parents during the study, absence of more than 2 sessions in group interactions and not compensating for missed sessions by participating in the sessions of other groups, consuming any medications during the study, any changes in the menstrual period (less than 3 days and more than 7 days), any changes in menstrual cycle length (less than 24 days and more than 35 days) and having stress during the study or in the last 3 months (such as death of the relatives, marriage or undergoing any surgical procedure).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mental and emotional symptoms of premenstrual syndrome. Timepoint: In the second step before the intervention and at the end of each month after the intervention (for 3 months). Method of measurement: Premenstrual Syndrome Screening Questionnaire.;Physical symptoms of premenstrual syndrome. Timepoint: In the second step before the intervention and at the end of each month after the intervention (for 3 months. Method of measurement: Premenstrual Syndrome Screening Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Individual's general health especially mental health. Timepoint: Before the intervention. Method of measurement: General Health Questionnaire (G.H.Q). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Akbarzadeh
Shiraz University of Medical Sciences
Outcome results
None listed